{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:44:10Z","timestamp":1793893450651,"version":"4.8.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Thyroid cancer is the most prevalent endocrine malignancy, with its global incidence increasing annually in recent years. Papillary carcinoma is the most common subtype, frequently accompanied by cervical lymph node metastasis early on. Central lymph node metastasis (CLNM) is particularly the common metastasis form in this subtype, and the presence of lymph node metastasis correlates strongly with tumor recurrence. However, effective preoperative assessment methods for CLNM in patients with papillary thyroid carcinoma (PTC) remain lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from 400 patients diagnosed with PTC between January 1, 2018, and January 1, 2022, at the Shandong Provincial Hospital were retrospectively analyzed. This data included clinicopathological information of the patients, such as thyroid function, BRAF V600E mutation, whether complicated with Hashimoto\u2019s thyroiditis, and the presence of capsular invasion. Univariate and multivariate logistic regression analyses were performed to assess the risk factors associated with cervical CLNM in patients with PTC. Subsequently, a clinical prediction model was constructed, and prognostic risk factors were identified based on univariate and multivariate Cox regression analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Univariate and multivariate analyses identified that age &amp;gt;45 years (P=0.014), body mass index \u226525 (P=0.008), tumor size \u22651 cm (P=0.001), capsular invasion (P=0.001), and the presence of BRAF V600E mutation (P&amp;lt;0.001) were significantly associated with an increased risk of CLNM. Integrating these factors into the nomogram revealed an area-under-the-curve of 0.791 (95% confidence interval 0.735\u20130.846) and 0.765 (95% confidence interval: 0.677\u20130.852) for the training and validation sets, respectively, indicating strong discriminative abilities. Subgroup analysis further confirmed that patients with papillary thyroid microcarcinoma and BRAF V600E mutations who underwent therapeutic central compartment neck dissection had significantly better 3-year disease-free survival than those who had prophylactic central compartment neck dissection (P&amp;lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study revealed that age &amp;gt;45 years, body mass index \u226525, tumor size \u22651 cm, BRAF V600E mutation, and capsular invasion are the related risk factors for CLNM in patients with PTC. For patients with clinically nodal-negative (cN0) papillary thyroid microcarcinoma, accurately identifying the BRAF V600E mutation is essential for guiding the central lymph node dissection approach and subsequent treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2023.1288527","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T05:53:40Z","timestamp":1700200420000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study"],"prefix":"10.3389","volume":"14","author":[{"given":"Jiachen","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchen","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingsong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1530\/erc-15-0555","article-title":"Treatment of advanced thyroid cancer with targeted therapies: ten years of experience","volume":"23","author":"Viola","year":"2016","journal-title":"Endocrine-Related Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41574-019-0263-x","article-title":"Geographic influences in the global rise of thyroid cancer","volume":"16","author":"Kim","year":"2019","journal-title":"Nat Rev Endocrinology."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0643","article-title":"Trends in thyroid surgery and guideline-concordant care in the United States, 2007\u20132018","volume":"31","author":"Toumi","year":"2021","journal-title":"Thyroid"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.713475","article-title":"Preoperatively predicting the central lymph node metastasis for papillary thyroid cancer patients with Hashimoto\u2019s thyroiditis","volume":"12","author":"Min","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.789310","article-title":"Predictors and a prediction model for central cervical lymph node metastasis in papillary thyroid carcinoma (cN0)","volume":"12","author":"Gao","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.716728","article-title":"Risk factors and a prediction model of lateral lymph node metastasis in CN0 papillary thyroid carcinoma patients with 1-2 central lymph node metastases","volume":"12","author":"Wang","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.666315","article-title":"A nomogram based on clinical and ultrasound characteristics to predict central lymph node metastasis of papillary thyroid carcinoma","volume":"12","author":"Feng","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J Clin"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/00015458.2019.1576447","article-title":"Investigating the prevalence of risk factors of papillary thyroid carcinoma recurrence and disease-free survival after thyroidectomy and central neck dissection in Iranian patients","volume":"120","author":"Arianpoor","year":"2019","journal-title":"Acta Chirurgica Belgica."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-017-4158-5","article-title":"Macrometastasis in papillary thyroid cancer patients is associated with higher recurrence in lateral neck nodes","volume":"42","author":"Kim","year":"2017","journal-title":"World J Surgery."},{"key":"B12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/eje-11-0499","article-title":"RET\/PTC rearrangement in benign and Malignant thyroid diseases: a clinical standpoint","volume":"165","author":"Marotta","year":"2011","journal-title":"Eur J Endocrinology."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0053","article-title":"Estrogen and its role on thyroid cancer","volume":"21","author":"Derwahl","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: A practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01524-5","article-title":"Construction and validation of a nomogram for predicting cervical lymph node metastasis in classic papillary thyroid carcinoma","volume":"44","author":"Feng","year":"2021","journal-title":"J Endocrinological Invest"},{"key":"B16","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1186\/s12885-019-5835-6","article-title":"Risk factor analysis for predicting cervical lymph node metastasis in papillary thyroid carcinoma: a study of 966 patients","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1507\/endocrj.ej12-0044","article-title":"Relationship between prognosis of pa","volume":"59","author":"Ito","year":"2012","journal-title":"Endocr J SO"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)30054-x","article-title":"Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19\u00b72 million participants","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA: A Cancer J Clin"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.767245","article-title":"The relationship between body mass index and different regional patterns of lymph node involvement in papillary thyroid cancers","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.772071","article-title":"The impact of coexistent Hashimoto\u2019s thyroiditis on central compartment lymph node metastasis in papillary thyroid carcinoma","volume":"12","author":"Liu","year":"2021","journal-title":"Front Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.18526","article-title":"Prevalence of Hashimoto thyroiditis in adults with papillary thyroid cancer and its association with cancer recurrence and outcomes","volume":"4","author":"Xu","year":"2021","journal-title":"JAMA Network Open"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02194-8","article-title":"Risk stratification for lateral involvement in papillary thyroid carcinoma patients with central lymph node metastasis","volume":"68","author":"Heng","year":"2020","journal-title":"Endocrine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00277","article-title":"The prognostic value of tumor multifocality in clinical outcomes of papillary thyroid cancer","volume":"102","author":"Wang","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO classification of thyroid neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocrine Pathology."},{"key":"B26","article-title":"High prevalence of BRAF mutations","volume":"63","author":"Kimura","year":"2003","journal-title":"Cancer Res SO"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0147","article-title":"Quantification of BRAF V600E alleles","volume":"21","author":"Kim","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1245\/s10434-012-2614-x","article-title":"BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer","volume":"20","author":"Zeiger","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2018.0125","article-title":"Thyroid carcinoma","volume":"12","author":"Tuttle","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2018.0125","article-title":"Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1,587 patients","volume":"16","author":"Xiangqian","year":"2019","journal-title":"Cancer Biol Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v14.i7.247","article-title":"Role of prophylactic central neck lymph node dissection for papillary thyroid carcinoma in the era of de-escalation","volume":"14","author":"Pavlidis","year":"2023","journal-title":"World J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1034047","article-title":"A LASSO-based model to predict central lymph node metastasis in preoperative patients with cN0 papillary thyroid cancer","volume":"13","author":"Zhao","year":"2023","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2016.02.093","article-title":"Predictive factors for central lymph node metastasis in patients with cN0 papillary thyroid carcinoma: A systematic review and meta-analysis","volume":"28","author":"Ma","year":"2016","journal-title":"Int J Surgery."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1530\/eje-07-0896","article-title":"Thyroid papillary microcarcinoma: a descriptive and meta-analysis study","volume":"159","author":"Roti","year":"2008","journal-title":"Eur J Endocrinology."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1288527\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T05:53:44Z","timestamp":1700200424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1288527\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":34,"alternative-id":["10.3389\/fendo.2023.1288527"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1288527","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,17]]},"article-number":"1288527"}}